The company sells several products, including GLP-1s (Representational image)
US telehealth startup Medvi has come under scrutiny after the New York Times published an article about its staggering growth, projecting $1.8 billion in sales in 2026, with only two employees.
The founder, Matthew Gallagher, credits AI for building the website, targeting ads, and maintaining the lean workforce. The company sells several products, including GLP-1s.
However, critics argue the startup’s foundations are built on a network of affiliate marketers using deceptive AI-generated content.
Investigation by outlets like Futurism and Business Insider has revealed the use of fake patient before-and-after photos and AI-generated testimonials featuring nonexistent doctors.
Medvi is also under fire from regulators and consumer advocates. The FDA issued a warning letter regarding its false or misleading claims, and the company is currently defending two lawsuits over illegal spam.
Gallagher has blamed rogue affiliates for the violations.
The controversy highlights the friction between AI scaling and safety standards of medical practice.